cannabidiol transdermal gel (BTX1204) / Botanix Pharma - LARVOL DELTA

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - P2; N=200; Completed; Sponsor: Botanix Pharmaceuticals; Recruiting ➔ Completed

Clinical • Trial completion

BRIEF-Botanix Pharmaceuticals requests trading halt (Reuters) - "Requests trading halt pending announcement in relation to results of BTX 1204 phase 2 atopic dermatitis study."

Commercial

Brief-Botanix Pharmaceuticals says BTX 1204 did not meet primary endpoint in phase 2 study (Reuters) - "BTX 1204 did not meet primary endpoint in phase 2 study for safety & efficacy in patients with moderate atopic dermatitis."

P2 data

Why the Botanix share price is sagging today (The Motley Fool) - "Botanix’s BTX 1503 Phase 2 acne and BTX 1204 Phase 2 atopic dermatitis studies remain on track for completion...During the quarter, Botanix had net cash outflows of A$4.6m with $4.3m invested in R&D activities, primarily to progress the two Phase 2 clinical studies (BTX 1503 and BTX 1204). At the end of the quarter, Botanix held $4.7m in cash. Forecast cash outflows for R&D activities is estimated to be $5.7m for the upcoming quarter."

Commercial • Trial status

Botanix receives commitments for A$40m in US-led institutional placement and announces appointment of key US management executives (Businesswire) - "Botanix has received firm commitments for A$40m at an offer price of A$0.21 per fully paid ordinary share....The funds from the Placement will enable Botanix to continue to execute its key clinical development programmes....Botanix is now fully funded to...undertake supportive studies that will be required prior to commencement of Phase 3 studies for...BTX 1204 (atopic dermatitis). Botanix remains on track to complete the Phase 2 BTX 1503 in 3Q CY2019 and BTX 1204 in 4Q CY2019, with data readouts to follow completion of these studies shortly thereafter."

Financing • P2 data • Trial status

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - P2; N=200; Recruiting; Sponsor: Botanix Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - P2; N=200; Not yet recruiting; Sponsor: Botanix Pharmaceuticals

Clinical • New P2 trial